DiscoverMarkets & Money Today | 2 Min News | The Daily News Now!Cellectar Biosciences stock soars after FDA grants rare pediatric designation By Investing.com
Cellectar Biosciences stock soars after FDA grants rare pediatric designation By Investing.com

Cellectar Biosciences stock soars after FDA grants rare pediatric designation By Investing.com

Update: 2025-10-27
Share

Description

Hope for kids with brain cancer? Cellectar Biosciences stock skyrockets 27% after FDA grants Rare Pediatric Disease Designation to its iopofosine I-131 therapy. Promising trial data shows significantly longer survival rates in children with aggressive brain tumors, paving the way for potential breakthrough treatment. Will this be the game-changer families desperately need?

The Daily News Now! — Every city. Every story. AI-powered.


Hosted on Acast. See acast.com/privacy for more information.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Cellectar Biosciences stock soars after FDA grants rare pediatric designation By Investing.com

Cellectar Biosciences stock soars after FDA grants rare pediatric designation By Investing.com